Navigation Links
IntelliCell BioSciences Announces It Will Present and Run Workshop at the 10th Annual Commercialization of Regenerative Medicine in London
Date:11/14/2012

NEW YORK, Nov. 14, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (SVFC) announced today it will present at the Marcus Evans 10th Annual Commercialization of Regenerative Medicine in London, UK on the 28-30th November 2012.  The Company will also be conducting a half-day pre-conference workshop addressing market entry strategies for emerging regenerative medicine companies.

IntelliCell's EVP Clinical Development, Robert Sexauer, stated "Our Company is very pleased to be participating in this well established conference for emerging regenerative medicine technologies.  Over the past several years, our management team has processed over 10,000 autologous cellular products and we are happy to share our insights regarding market entry strategies for emerging companies in our industry.  We want to see the entire regenerative medicine industry continue to develop compliant processes, systems, and practices for better medicine"

Dr. Steven Victor, Chairman and CEO of IntelliCell stated "This is an exciting time for regenerative medicine companies.  IntelliCell is taking a thought leadership role in the translation of technologies from the research laboratories and into clinical practice.  Our objective is to continue to harmonize the requirements of regulators, clinicians, and patients receiving these profound new treatments."

About IntelliCell BioSciences

IntelliCell BioSciences is a Regenerative Medicine company developing novel technologies that address the regenerative, curative, and preventative conditions of disease states with high unmet clinical needs.  The Company has several patent pending applications including an industry unique method of obtaining autologous stromal vascular fraction cells (SVF) from the vasculature surrounding adipose tissue containing adult stem cells and a robust population of regenerative healing cells.  The Company is also pioneering the development of autologous and allogeneic cells from living and non-living tissue donors for research purposes.  IntelliCell is planning a series of in-human clinical studies with top tier universities for the treatment of osteoarthritis, multiple sclerosis, lower limb ischemic wounds, and gum regeneration in the oral cavity as well as medical aesthetics.  The Company has developed a first in class cGTP cellular processing facility in New York City, purpose built and designed to be fully integrated into its ambulatory surgery center. 

Forward-Looking Statements
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

Contacts:

IntelliCell BioSciences, Inc.
Angela Metelitsa
Email Contact:  ametelitsa@intellicellbiosciences.com 
(646) 576-8708  

 


'/>"/>
SOURCE IntelliCell BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. IntelliCell BioSciences Announces Myron Z. Holubiak Joins the IntelliCell BioSciences Board of Directors
2. IntelliCell BioSciences Announces Collaborative Agreement with the University of Florida on Stem Cell and Tissue Repair Research
3. IntelliCell BioSciences Expands Management Team
4. IntelliCell BioSciences Signs Technology Licensing Agreement with Stem Cells 21 Thailand
5. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
6. Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
7. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
8. Neurocrine Biosciences Reports Third Quarter 2012 Results
9. AMRI Announces Strategic Contract with Knopp Biosciences
10. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
11. Neurocrine Biosciences Reports Second Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... ... February 19, 2017 , ... Expanding Portfolio to Include Lab ... equipment with the goal of expanding the reach of its quality and precision ... water analysis meters were introduced into the market in 2014. , The OHAUS ...
(Date:2/18/2017)... IL (PRWEB) , ... February 17, 2017 , ... ... Blood and Marrow Transplantation (ASBMT) and the Center for International Blood & Marrow ... Convention Center in Orlando, Fla. , The combined scientific sessions offer ...
(Date:2/18/2017)... , Feb 17, 2017 Research and Markets ... Business Report" report to their offering. ... The report provides separate comprehensive analytics ... , and Rest of World. Annual estimates and forecasts are ... analysis is provided for these markets. Market data and analytics are ...
(Date:2/17/2017)... FREMONT, Calif. , Feb. 17, 2017 /PRNewswire/ ... pleased to announce development of a novel system ... in collaboration with the University of Rochester (NY, ... ). The new system is able to ... cancer biomarker, HER2 (Human epidermal growth factor receptor-2) ...
Breaking Biology Technology:
(Date:1/26/2017)... CITY , Jan. 26, 2017  Crossmatch, a ... unveiled a new solution aimed at combatting fraud, waste ... solution was introduced at the Action on Disaster Relief ... key meeting point for UN agencies and foreign assistance ... Fraud, waste and abuse are a largely unacknowledged ...
(Date:1/23/2017)...  The latest mobile market research from Acuity Market ... The quarterly average price of a biometric smartphone decreased ... 2016.  There are now 120 sub-$150 models on the ... just 28 a year ago at an average price ... Most , Acuity Market Intelligence Principal, "Biometric Smartphones are ...
(Date:1/18/2017)... MedNet Solutions , an innovative ... spectrum of clinical research, is proud to announce ... the organization in terms of corporate growth, outside ... and services. The company,s exceptional achievements can be ... iMedNet ™ – MedNet,s ...
Breaking Biology News(10 mins):